Published in Mol Cell on December 08, 2006
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol (2010) 7.95
Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell (2011) 4.91
Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol (2007) 3.86
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J (2011) 3.06
BH3-triggered structural reorganization drives the activation of proapoptotic BAX. Mol Cell (2010) 2.89
Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci U S A (2008) 2.67
A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev (2007) 1.97
Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol (2011) 1.73
Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb Perspect Biol (2013) 1.73
Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis. J Cell Sci (2009) 1.70
Many players in BCL-2 family affairs. Trends Biochem Sci (2014) 1.64
Bax dimerizes via a symmetric BH3:groove interface during apoptosis. Cell Death Differ (2011) 1.60
Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem (2008) 1.55
Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ (2013) 1.54
Direct activation of full-length proapoptotic BAK. Proc Natl Acad Sci U S A (2013) 1.53
BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem (2010) 1.52
Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res (2010) 1.48
The secrets of the Bcl-2 family. Cell Death Differ (2012) 1.48
BID-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol (2013) 1.45
Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. J Biol Chem (2010) 1.36
Assembly of the mitochondrial apoptosis-induced channel, MAC. J Biol Chem (2009) 1.35
Bax forms an oligomer via separate, yet interdependent, surfaces. J Biol Chem (2010) 1.27
The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. Genes Cancer (2011) 1.23
Organization of the mitochondrial apoptotic BAK pore: oligomerization of the BAK homodimers. J Biol Chem (2013) 1.16
The holo-apoptosome: activation of procaspase-9 and interactions with caspase-3. Structure (2011) 1.15
Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem Biol (2013) 1.15
Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol (2014) 1.13
Assembly of the Bak apoptotic pore: a critical role for the Bak protein α6 helix in the multimerization of homodimers during apoptosis. J Biol Chem (2013) 1.12
Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J Biol Chem (2009) 1.12
Tyrosine dephosphorylation is required for Bak activation in apoptosis. EMBO J (2010) 1.09
Reconstitution of proapoptotic BAK function in liposomes reveals a dual role for mitochondrial lipids in the BAK-driven membrane permeabilization process. J Biol Chem (2011) 1.08
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta (2015) 1.05
Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function. Cell Death Differ (2014) 1.03
Where killers meet--permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol (2013) 1.03
Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis. J Biol Chem (2011) 1.02
Apoptotic regulation by MCL-1 through heterodimerization. J Biol Chem (2010) 1.02
Structural biology of the Bcl-2 family and its mimicry by viral proteins. Cell Death Dis (2013) 1.01
Death upon a kiss: mitochondrial outer membrane composition and organelle communication govern sensitivity to BAK/BAX-dependent apoptosis. Chem Biol (2013) 1.00
Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane. Proc Natl Acad Sci U S A (2014) 0.99
Mitochondrial dynamics: functional link with apoptosis. Int J Cell Biol (2012) 0.99
Apoptosis: Stabbed in the BAX. Nature (2008) 0.98
Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. Sci Rep (2012) 0.96
Translocation of a Bak C-terminus mutant from cytosol to mitochondria to mediate cytochrome C release: implications for Bak and Bax apoptotic function. PLoS One (2012) 0.95
BAK activation is necessary and sufficient to drive ceramide synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins. Biochem J (2013) 0.95
BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis. Cell Rep (2013) 0.94
A new view of the lethal apoptotic pore. PLoS Biol (2012) 0.94
BAK/BAX activation and cytochrome c release assays using isolated mitochondria. Methods (2013) 0.94
Calpain-generated natural protein fragments as short-lived substrates of the N-end rule pathway. Proc Natl Acad Sci U S A (2014) 0.90
Bak apoptotic pores involve a flexible C-terminal region and juxtaposition of the C-terminal transmembrane domains. Cell Death Differ (2015) 0.89
Evaluation of the BH3-only protein Puma as a direct Bak activator. J Biol Chem (2013) 0.88
"Licensed to kill": tyrosine dephosphorylation and Bak activation. Cell Cycle (2011) 0.88
Identification of the regions of the HPV 5 E6 protein involved in Bak degradation and inhibition of apoptosis. Int J Cancer (2008) 0.87
Augmented generation of protein fragments during wakefulness as the molecular cause of sleep: a hypothesis. Protein Sci (2012) 0.86
Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction. Cell Death Dis (2015) 0.84
The functional differences between pro-survival and pro-apoptotic B cell lymphoma 2 (Bcl-2) proteins depend on structural differences in their Bcl-2 homology 3 (BH3) domains. J Biol Chem (2014) 0.84
Heterodimerization of BAK and MCL-1 activated by detergent micelles. J Biol Chem (2010) 0.83
Pro-apoptotic Bax molecules densely populate the edges of membrane pores. Sci Rep (2016) 0.82
Bak apoptotic function is not directly regulated by phosphorylation. Cell Death Dis (2013) 0.82
Dynamics of Bcl-xL in water and membrane: molecular simulations. PLoS One (2013) 0.80
Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes Dev (2015) 0.80
Human Bop is a novel BH3-only member of the Bcl-2 protein family. Protein Cell (2012) 0.79
Reconstitution and engineering of apoptotic protein interactions on the bacterial cell surface. J Mol Biol (2009) 0.79
An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1. Br J Cancer (2013) 0.79
Dynamical systems analysis of mitochondrial BAK activation kinetics predicts resistance to BH3 domains. PLoS One (2008) 0.78
The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane. FEBS J (2016) 0.78
Physiological restraint of Bak by Bcl-xL is essential for cell survival. Genes Dev (2016) 0.77
Improving the therapeutic potential of endostatin by fusing it with the BAX BH3 death domain. Cell Death Dis (2014) 0.77
Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Cell Death Dis (2016) 0.77
Charge profile analysis reveals that activation of pro-apoptotic regulators Bax and Bak relies on charge transfer mediated allosteric regulation. PLoS Comput Biol (2012) 0.76
Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies. Nat Commun (2016) 0.76
Disordered clusters of Bak dimers rupture mitochondria during apoptosis. Elife (2017) 0.75
Structural biology of the intrinsic cell death pathway: what do we know and what is missing? Comput Struct Biotechnol J (2012) 0.75
Epi-reevesioside F inhibits Na+/K+-ATPase, causing cytosolic acidification, Bak activation and apoptosis in glioblastoma. Oncotarget (2015) 0.75
BAX to basics: How the BCL2 gene family controls the death of retinal ganglion cells. Prog Retin Eye Res (2017) 0.75
BAK α6 permits activation by BH3-only proteins and homooligomerization via the canonical hydrophobic groove. Proc Natl Acad Sci U S A (2017) 0.75
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Coupling of the nucleus and cytoplasm: role of the LINC complex. J Cell Biol (2005) 6.47
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res (2004) 5.21
Spreading the word. Nature (2007) 5.03
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science (2013) 2.84
The structure of human argonaute-2 in complex with miR-20a. Cell (2012) 2.83
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol (2010) 2.74
Nesprin 4 is an outer nuclear membrane protein that can induce kinesin-mediated cell polarization. Proc Natl Acad Sci U S A (2009) 2.59
Micro-optical sectioning tomography to obtain a high-resolution atlas of the mouse brain. Science (2010) 2.47
The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J (2012) 2.13
An NMR approach to structural proteomics. Proc Natl Acad Sci U S A (2002) 1.95
Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr Res (2006) 1.89
A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A. Am J Med Genet A (2004) 1.79
ABO3, a WRKY transcription factor, mediates plant responses to abscisic acid and drought tolerance in Arabidopsis. Plant J (2010) 1.74
Protein quality control in the ER: the recognition of misfolded proteins. Semin Cell Dev Biol (2010) 1.69
A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci U S A (2003) 1.69
The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. Cell Res (2012) 1.66
A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood (2014) 1.66
The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood (2011) 1.65
Poly(A) binding protein (PABP) homeostasis is mediated by the stability of its inhibitor, Paip2. EMBO J (2006) 1.64
Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol Cell (2007) 1.60
Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.60
SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination. Mol Cell (2009) 1.59
Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature (2008) 1.55
Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood (2007) 1.55
Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product. J Biol Chem (2006) 1.55
Exogenous silicon (Si) increases antioxidant enzyme activity and reduces lipid peroxidation in roots of salt-stressed barley (Hordeum vulgare L.). J Plant Physiol (2003) 1.53
Structural basis of ligand recognition by PABC, a highly specific peptide-binding domain found in poly(A)-binding protein and a HECT ubiquitin ligase. EMBO J (2003) 1.52
Plant phenomics and high-throughput phenotyping: accelerating rice functional genomics using multidisciplinary technologies. Curr Opin Plant Biol (2013) 1.52
Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res (2011) 1.51
BH3-ligand regulates access of MCL-1 to its E3 ligase. FEBS Lett (2005) 1.49
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood (2010) 1.48
BID-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol (2013) 1.45
Reverse-phase protein array analysis to identify biomarker proteins in human pancreatic cancer. Dig Dis Sci (2013) 1.43
RTE1 is a Golgi-associated and ETR1-dependent negative regulator of ethylene responses. Plant Physiol (2007) 1.39
Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med (2011) 1.38
A structural overview of the PDI family of proteins. FEBS J (2010) 1.38
Poly(A) nuclease interacts with the C-terminal domain of polyadenylate-binding protein domain from poly(A)-binding protein. J Biol Chem (2007) 1.37
Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol Cancer (2009) 1.35
Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis (2009) 1.35
Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology (2012) 1.34
Receptor signal output mediated by the ETR1 N terminus is primarily subfamily I receptor dependent. Plant Physiol (2006) 1.34
Structural basis of binding of P-body-associated proteins GW182 and ataxin-2 by the Mlle domain of poly(A)-binding protein. J Biol Chem (2010) 1.34
Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology (2009) 1.34
Connecdenn, a novel DENN domain-containing protein of neuronal clathrin-coated vesicles functioning in synaptic vesicle endocytosis. J Neurosci (2006) 1.33
Crystal structure of the bb' domains of the protein disulfide isomerase ERp57. Structure (2006) 1.33
Solution structure of the bb' domains of human protein disulfide isomerase. FEBS J (2009) 1.32
Health care in China: improvement, challenges, and reform. Chest (2013) 1.31
Structure of Rpn10 and its interactions with polyubiquitin chains and the proteasome subunit Rpn12. J Biol Chem (2010) 1.31
Poly(A)-binding protein-interacting protein 1 binds to eukaryotic translation initiation factor 3 to stimulate translation. Mol Cell Biol (2008) 1.30
IL-2 and autocrine IL-4 drive the in vivo development of antigen-specific Th2 T cells elicited by nematode parasites. J Immunol (2005) 1.29
Structural basis of carbohydrate recognition by calreticulin. J Biol Chem (2010) 1.25
Requirements for the development of IL-4-producing T cells during intestinal nematode infections: what it takes to make a Th2 cell in vivo. Immunol Rev (2004) 1.24
Transposons inactivate biosynthesis of the nonribosomal peptide microcystin in naturally occurring Planktothrix spp. Appl Environ Microbiol (2006) 1.24
Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res (2009) 1.24
Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc Natl Acad Sci U S A (2012) 1.23
CADgene: a comprehensive database for coronary artery disease genes. Nucleic Acids Res (2010) 1.23
The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J Biol Chem (2007) 1.22
Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J Biol Chem (2004) 1.22
Hydrophilic Cu9S5 nanocrystals: a photothermal agent with a 25.7% heat conversion efficiency for photothermal ablation of cancer cells in vivo. ACS Nano (2011) 1.21
Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling. Cytotechnology (2009) 1.21
Upconversion luminescent materials: advances and applications. Chem Rev (2014) 1.19
Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res (2012) 1.19
Solution structure of human BCL-w: modulation of ligand binding by the C-terminal helix. J Biol Chem (2003) 1.19
Chromosome instability and tumor predisposition inversely correlate with BLM protein levels. DNA Repair (Amst) (2003) 1.18
High-throughput measurement of rice tillers using a conveyor equipped with x-ray computed tomography. Rev Sci Instrum (2011) 1.18
Controllable N-doping of graphene. Nano Lett (2010) 1.18
Laser speckle imaging of blood flow in microcirculation. Phys Med Biol (2004) 1.18
Surface plasmon-coupled emission: what can directional fluorescence bring to the analytical sciences? Annu Rev Anal Chem (Palo Alto Calif) (2012) 1.17
Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood (2010) 1.17
The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasite Heligmosomoides polygyrus. J Immunol (2003) 1.17
Specific interaction of ERp57 and calnexin determined by NMR spectroscopy and an ER two-hybrid system. EMBO J (2004) 1.16
Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infect Dis (2013) 1.16
sRNATarBase: a comprehensive database of bacterial sRNA targets verified by experiments. RNA (2010) 1.14
Sequence-structure relationships in polysaccharide co-polymerase (PCP) proteins. Trends Biochem Sci (2008) 1.14
AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med (2011) 1.14
Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. Mol Cell (2012) 1.13
Crystal structure of a dodecameric FMN-dependent UbiX-like decarboxylase (Pad1) from Escherichia coli O157: H7. Protein Sci (2004) 1.13
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat (2012) 1.12
An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol (2005) 1.12
Solution structure of the PDZ2 domain from cytosolic human phosphatase hPTP1E complexed with a peptide reveals contribution of the beta2-beta3 loop to PDZ domain-ligand interactions. J Mol Biol (2002) 1.11
ERp57 does not require interactions with calnexin and calreticulin to promote assembly of class I histocompatibility molecules, and it enhances peptide loading independently of its redox activity. J Biol Chem (2009) 1.11
Molecular determinants of PAM2 recognition by the MLLE domain of poly(A)-binding protein. J Mol Biol (2010) 1.11
Metabolic imaging of tumors using intrinsic and extrinsic fluorescent markers. Biosens Bioelectron (2004) 1.10
Interdomain allostery promotes assembly of the poly(A) mRNA complex with PABP and eIF4G. Mol Cell (2012) 1.10
Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res (2012) 1.09
Structural basis of substrate recognition and specificity in the N-end rule pathway. Nat Struct Mol Biol (2010) 1.09
Structural model of the BCL-w-BID peptide complex and its interactions with phospholipid micelles. Biochemistry (2006) 1.08
Structural basis of defects in the sacsin HEPN domain responsible for autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). J Biol Chem (2011) 1.08
Comparative peptide binding studies of the PABC domains from the ubiquitin-protein isopeptide ligase HYD and poly(A)-binding protein. Implications for HYD function. J Biol Chem (2006) 1.07
Combinatorial Optimization of (Lu₁₋(x)Gd(x))₃Al₅O₁₂:Ce₃(y) yellow phosphors as precursors for ceramic scintillators. ACS Comb Sci (2010) 1.07